Companies:
53,102
Total Market Cap:
170173916814658.33
Global Rank
#40471
Country Rank
#110
Market Cap
13.21 M
Price
0.295
Change (%)
4.45%
Volume
19,535
Celyad Oncology SA's latest marketcap:
13.21 M
As of 07/17/2026, Celyad Oncology SA's market capitalization has reached $13.21 M. According to our data, Celyad Oncology SA is the 40471th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 13.21 M |
| Revenue (ttm) | 24,013.5 |
| Net Income (ttm) | 949,105 |
| Shares Out | 44.76 M |
| EPS (ttm) | 0.02 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 09/23/2026 |
Market Cap Chart
Data Updated: 07/17/2026
Celyad Oncology SA's yearly market capitalization.
Celyad Oncology SA has seen its market value drop from €238.67 M to €11.55 M since 2014, representing a total decrease of 95.16% and an annual compound decline rate (CAGR) of 23.08%.
| Date | Market Cap(€) | Market Cap(USD) | Change (%) | Global Rank |
|---|---|---|---|---|
| 07/17/2026 | €11.55 M | $13.21 M | 54.12% | 40471 |
| 12/31/2025 | €7.61 M | $8.83 M | -74.2% | 34997 |
| 12/31/2024 | €29.5 M | $30.54 M | 82.56% | 31381 |
| 12/29/2023 | €16.16 M | $17.83 M | 41.33% | 34327 |
| 12/30/2022 | €11.43 M | $12.24 M | -85.6% | 35082 |
| 12/31/2021 | €79.42 M | $90.27 M | -13.96% | 23774 |
| 12/31/2020 | €92.3 M | $0 | -31.75% | 19918 |
| 12/31/2019 | €135.24 M | $151.64 M | -31.74% | 16046 |
| 12/31/2018 | €198.12 M | $227.17 M | -41.95% | 13297 |
| 12/29/2017 | €341.32 M | $409.38 M | 105.77% | 11370 |
Company Profile
About Celyad Oncology SA
Celyad Oncology SA is a biopharmaceutical company dedicated to pioneering innovative chimeric antigen receptor T (CAR-T) cell therapies for cancer treatment. Headquartered in Mont-Saint-Guibert, Belgium, the company was founded in 2004 and rebranded from Celyad SA to Celyad Oncology SA in June 2020.
Key Research & Development Focus
- shRNA Non-Gene-Edited Technology: Enables the development of allogenic CAR T-cells by modulating TCR genes without gene editing.
- Multi-Specific CAR T-Cell Platform: Targets the NKG2D receptor for enhanced therapeutic potential.
- NKG2D-Based CAR T-Cell Therapies: Focused on leveraging the NKG2D receptor for cancer immunotherapy.
- B7-H6 Targeting CAR T-Cell Therapies: Aims to develop treatments targeting the B7-H6 protein.
Strategic Collaborations
- Novartis International AG: Licensing agreement for U.S. patents related to allogeneic CAR-T cells.
- Horizon Discovery/PerkinElmer: Research, development, and licensing partnership for shRNA reagents to modulate target gene expression.
Frequently Asked Questions
-
What is Celyad Oncology SA's (EBR-CYAD) current market cap?As of 07/17/2026, Celyad Oncology SA (including the parent company, if applicable) has an estimated market capitalization of $13.21 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Celyad Oncology SA (EBR-CYAD) rank globally by market cap?Celyad Oncology SA global market capitalization ranking is approximately 40471 as of 07/17/2026. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.